BlackThorn Therapeutics

Napo Pharmaceuticals, Inc. is a San Francisco-based company dedicated to developing and commercializing prescription medicines that provide essential supportive care for individuals undergoing treatment for diseases like cancer. Their mission is to improve the comfort, quality of life, and dignity of patients experiencing treatment-related gastrointestinal distress, particularly overactive bowel symptoms such as chronic diarrhea, urgency, and incontinence. Napo Pharmaceuticals is currently focused on their Phase 3 pivotal OnTarget trial of Mytesi crofelemer, a preventative treatment for chemotherapy-induced overactive bowel, with comprehensive results expected in Q1 2024. They also support investigator-initiated studies exploring the potential of crofelemer for rare disease indications like short bowel syndrome and microvillus inclusion disease. Napo Pharmaceuticals takes pride in their responsible harvesting practices, sourcing their medicines from plants in rainforest regions. Their prescription medicines work through a novel mechanism of action, inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract. The company is committed to uncovering medical solutions to serve those in need, advancing their understanding through high-quality research conducted by external investigators. Environmental sustainability and social responsibility are paramount to Napo Pharmaceuticals, as they prioritize the responsible harvesting of their products and share benefits with the local communities that contribute to their mission.Generated from the website

Jaguar Health, Inc., based in San Francisco, is dedicated to the discovery, development, and commercialization of plant-based prescription medicines aimed at addressing urgent global health needs. Their focus includes a strong pipeline of products targeting gastrointestinal diseases, particularly through their lead product, crofelemer, which is in advanced clinical trials for various indications. The company emphasizes sustainability and community benefit sharing as integral parts of their mission, ensuring that their endeavors not only address unmet medical needs but also support local communities worldwide. Jaguar Health continues to foster innovation in the realm of plant-based therapies, with a commitment to delivering viable healthcare solutions across multiple regions. Generated from the website

Senti Biosciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, CA, that focuses on developing innovative cancer therapeutics utilizing synthetic biology. Through its proprietary Gene Circuit technology, Senti Bio designs and optimizes biological systems that enable cells to sense their environment, compute decisions, and deliver targeted treatments, aiming to kill cancer cells while sparing healthy tissue. The company's lead product candidate, SENTI-202, is currently in clinical trials for the treatment of acute myeloid leukemia (AML). With a commitment to advancing cell therapy programs, Senti Bio is dedicated to addressing significant challenges in oncology and providing potentially lifesaving solutions for patients with incurable diseases. Generated from the website